Home > Insider Trading > Filing (0000899243-23-020076)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1609809	Seres Therapeutics Inc.	MCRB	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1435744	Thomas Desrosier	C/O Seres Therapeutics, Inc. 200 Sidney Street Cambridge MA 02139	Chief Legal Officer And Evp	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-10-27	13,501	$0.00	118,047	No	4	M	Direct
Common Stock	Disposition	2023-10-30	4,156	$1.35	113,891	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Acquisiton	2023-04-27	27,001	$0.00	27,001	$0.00
Common Stock	Restricted Stock Units	Disposition	2023-10-27	13,501	$0.00	13,501	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
27,001			No	4	A	Direct
13,500			No	4	M	Direct

Footnotes

On February 3, 2023, the reporting person was granted an award of 27,001 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 13,501 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 13,500 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on May 4, 2023, solely with the intent to cover taxes in connection with the vesting of the RSUs.
The price reported in column 4 is a weighted average of the price. These shares were sold in multiple transactions at prices ranging from $1.35 to $1.385, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date.